Filipendula ulmaria In 1897, Felix Hoffmann created a synthetically altered version of salicin, derived from the species, which caused less digestive upset than pure salicylic acid. The new drug, formally acetylsalicylic acid, was named aspirin by Hoffmann's employer Bayer AG after the old botanical name for meadowsweet, "Spiraea ulmaria". This gave rise to the class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs). A natural black dye can be obtained from the roots by using a copper mordant. A tea made from "Filipendula ulmaria" flowers or leaves has been used in traditional Austrian herbal medicine for the treatment of rheumatism, gout, infections,
Ellagic acid heart disease, and other medical problems. Ellagic acid has been identified by the U.S. Food and Drug Administration as a "fake cancer 'cure' consumers should avoid". A number of U.S.-based sellers of dietary supplements have received Warning Letters from the Food and Drug Administration for promoting ellagic acid with claims that violate the Federal Food, Drug, and Cosmetic Act. Urolithins, such as urolithin A, are microflora human metabolites of dietary ellagic acid derivatives that are under study as anti-cancer agents. Claims that ellagic acid can treat or prevent cancer in humans have not been proven. Ellagic acid Ellagic acid is